2018
Admission diagnoses among patients with heart failure: Variation by ACO performance on a measure of risk-standardized acute admission rates
Benchetrit L, Zimmerman C, Bao H, Dharmarajan K, Altaf F, Herrin J, Lin Z, Krumholz HM, Drye EE, Lipska KJ, Spatz ES. Admission diagnoses among patients with heart failure: Variation by ACO performance on a measure of risk-standardized acute admission rates. American Heart Journal 2018, 207: 19-26. PMID: 30404047, DOI: 10.1016/j.ahj.2018.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAccountable Care OrganizationsAgedAlgorithmsAnalysis of VarianceCardiovascular DiseasesComorbidityFemaleHeart FailureHospitalizationHumansInternational Classification of DiseasesMaleMedicare Part AMedicare Part BPatient AdmissionPatient DischargePatient-Centered CareSex DistributionTime FactorsUnited StatesConceptsHeart failureAccountable care organizationsMean admission rateAdmission ratesAdmission typeAcute admission ratesNoncardiovascular conditionsAdmission diagnosisCause admission ratesMedicare Shared Savings Program Accountable Care OrganizationsRate of hospitalizationPrincipal discharge diagnosisProportion of admissionsType of admissionNoncardiovascular causesHF admissionsHF patientsPerson yearsDischarge diagnosisPatient populationPatientsAdmissionKey quality metricDiagnosisSubstantial proportion
2017
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
Dhruva SS, Huang C, Spatz ES, Coppi AC, Warner F, Li SX, Lin H, Xu X, Furberg CD, Davis BR, Pressel SL, Coifman RR, Krumholz HM. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Hypertension 2017, 70: 94-102. PMID: 28559399, DOI: 10.1161/hypertensionaha.117.09221.Peer-Reviewed Original ResearchConceptsAntihypertensive therapySystolic blood pressure responseAdverse cardiovascular eventsFavorable initial responseBlood pressure responseHigher hazard ratioCardiovascular eventsCardiovascular outcomesHazard ratioMultivariable adjustmentHeart failureAverage SBPRandomized trialsOdds ratioCardiovascular diseaseSBPStudy participantsRespondersMonthsPressure responseImmediate respondersALLHATEarly responseInitial responseSuperior discrimination
2010
Thirty-Day Outcomes in Medicare Patients With Heart Failure at Heart Transplant Centers
Hummel SL, Pauli NP, Krumholz HM, Wang Y, Chen J, Normand SL, Nallamothu BK. Thirty-Day Outcomes in Medicare Patients With Heart Failure at Heart Transplant Centers. Circulation Heart Failure 2010, 3: 244-252. PMID: 20061519, DOI: 10.1161/circheartfailure.109.884098.Peer-Reviewed Original ResearchConceptsHeart transplant centersRisk-standardized readmission ratesRisk-standardized mortality ratesTransplant centersStandardized mortality ratioHeart failureTransplant hospitalsReadmission ratesMortality rateStandardized readmission ratioMortality ratioMedicare patientsReadmission ratiosMean standardized mortality ratioThirty-day outcomesCoronary artery bypassHeart failure careElderly Medicare patientsElderly Medicare beneficiariesArtery bypassElderly patientsTransplant candidatesMedicare beneficiariesHospitalPatients
2004
Relationship between heart failure treatment and development of worsening renal function among hospitalized patients11Guest Editor for this manuscript was Peter M. Okin, MD, New York Hosptial-Cornell Medical Center, New York, NY.
Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients11Guest Editor for this manuscript was Peter M. Okin, MD, New York Hosptial-Cornell Medical Center, New York, NY. American Heart Journal 2004, 147: 331-338. PMID: 14760333, DOI: 10.1016/j.ahj.2003.08.012.Peer-Reviewed Original ResearchConceptsFluid intake/outputHeart failureIntake/outputRenal functionHigh riskCalcium channel blocker useHistory of HFAssociation of medicationLoop diuretic dosesPredictors of WRFElevated creatinine levelEnzyme inhibitor useHeart failure treatmentCase-control studyUse of CCBGreater fluid lossHigher hematocrit levelsUncontrolled hypertensionBlocker useDiuretic dosesCreatinine levelsInhibitor useAcute treatmentDiabetes mellitusIndependent predictorsHospital Coronary Artery Bypass Graft Surgery Volume and Patient Mortality, 1998–2000
Rathore SS, Epstein AJ, Volpp KG, Krumholz HM. Hospital Coronary Artery Bypass Graft Surgery Volume and Patient Mortality, 1998–2000. Annals Of Surgery 2004, 239: 110-117. PMID: 14685108, PMCID: PMC1356200, DOI: 10.1097/01.sla.0000103066.22732.b8.Peer-Reviewed Original ResearchMeSH KeywordsAge DistributionAgedAnalysis of VarianceCause of DeathCoronary Artery BypassCoronary DiseaseFemaleHospital MortalityHumansIncidenceMaleMiddle AgedOdds RatioOutcome Assessment, Health CareProbabilityRegistriesRetrospective StudiesRisk AssessmentSampling StudiesSex DistributionTotal Quality ManagementUnited StatesConceptsLow-volume hospitalsMedium-volume hospitalsHigh-volume hospitalsSurgery volumeMortality riskMortality rateNational Inpatient Sample databaseRisk-standardized mortality ratesHospital CABG volumeHospital mortality rateRisk of mortalityLower mortality riskHealth care purchasersHospital mortalityMultivariable adjustmentVolume hospitalsBorderline significanceCABG volumeRetrospective analysisVolume groupMortality differencesPatientsHospitalLeapfrog GroupReliable marker
2003
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction
Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Journal Of The American College Of Cardiology 2003, 42: 201-208. PMID: 12875751, DOI: 10.1016/s0735-1097(03)00572-2.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAnalysis of VarianceAngiotensin-Converting Enzyme InhibitorsAspirinCase-Control StudiesCohort StudiesDrug Therapy, CombinationDrug UtilizationFemaleHumansKidney Failure, ChronicLogistic ModelsMaleMyocardial InfarctionPatient SelectionPeritoneal DialysisPlatelet Aggregation InhibitorsPractice Patterns, Physicians'PrognosisRenal DialysisRisk FactorsSurvival AnalysisTreatment OutcomeUnited StatesConceptsEnd-stage renal diseaseNon-ESRD patientsAcute myocardial infarctionESRD patientsRenal diseaseMyocardial infarctionAngiotensin-converting enzyme inhibitor therapyEnd-stage renal disease patientsAngiotensin-converting enzyme inhibitorStandard medical therapyEnzyme inhibitor therapyRenal disease patientsCooperative Cardiovascular Project databaseHigh-risk populationLogistic regression modelsEarly administrationInhibitor therapyMedical therapyACE inhibitorsAMI patientsPeritoneal dialysisPoor prognosisDisease patientsESRD databasePatientsQuality of Care of Medicare Beneficiaries with Acute Myocardial Infarction: Who Is Included in Quality Improvement Measurement?
Rathore SS, Wang Y, Radford MJ, Ordin DL, Krumholz HM. Quality of Care of Medicare Beneficiaries with Acute Myocardial Infarction: Who Is Included in Quality Improvement Measurement? Journal Of The American Geriatrics Society 2003, 51: 466-475. PMID: 12657065, DOI: 10.1046/j.1532-5415.2003.51154.x.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionReperfusion therapyOlder patientsMyocardial infarctionU.S. acute care hospitalsProportion of patientsAcute care hospitalsEffective treatment strategiesMedical record databaseOlder age groupsQuality of careQuality improvement measurementAdmission therapyDischarge therapyCare hospitalACE inhibitorsMedicare patientsTreatment strategiesRetrospective analysisMedicare beneficiariesPatientsEnzyme inhibitorsRecord databaseAge groupsTherapy
2002
Exercise Capacity and Mortality
Ko DT, Hebert PR, Krumholz HM. Exercise Capacity and Mortality. New England Journal Of Medicine 2002, 347: 288-290. PMID: 12141326, DOI: 10.1056/nejm200207253470413.Peer-Reviewed Original ResearchDifferences between African Americans and whites in the outcome of heart failure: Evidence for a greater functional decline in African Americans
Vaccarino V, Gahbauer E, Kasl SV, Charpentier PA, Acampora D, Krumholz HM. Differences between African Americans and whites in the outcome of heart failure: Evidence for a greater functional decline in African Americans. American Heart Journal 2002, 143: 1058-1067. PMID: 12075264, DOI: 10.1067/mhj.2002.122123.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAgedAnalysis of VarianceBlack PeopleCohort StudiesFemaleHealth Services AccessibilityHeart FailureHospitalizationHumansIncomeMaleMiddle AgedOutcome Assessment, Health CareProportional Hazards ModelsProspective StudiesQuality of Health CareSocioeconomic FactorsWhite PeopleConceptsGreater functional declineHeart failureCare indicatorsFunctional declineAfrican AmericansSelf-reported health statusSigns of decompensationDecompensated heart failureHistory of hypertensionProspective cohort studyVentricular ejection fractionDaily living functionAfrican American patientsDaily living functioningRenal insufficiencyBaseline characteristicsCohort studyConsecutive patientsEjection fractionHospital admissionFunctional statusAmerican patientsPoor courseLiving functioningHigh risk
1999
Use of critical pathways to improve the care of patients with acute myocardial infarction11Dr. Krumholz is a Paul Beeson Faculty Scholar. This article was written by CDR Eric S. Holmboe while a fellow in the Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine. The views expressed in this article are those of the author and do not reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.
Holmboe E, Meehan T, Radford M, Wang Y, Marciniak T, Krumholz H. Use of critical pathways to improve the care of patients with acute myocardial infarction11Dr. Krumholz is a Paul Beeson Faculty Scholar. This article was written by CDR Eric S. Holmboe while a fellow in the Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine. The views expressed in this article are those of the author and do not reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. The American Journal Of Medicine 1999, 107: 324-331. PMID: 10527033, DOI: 10.1016/s0002-9343(99)00239-9.Peer-Reviewed Original ResearchConceptsLength of stayEvidence-based medical therapyProportion of patientsMyocardial infarctionMedical therapyMedicare patientsMain endpointCritical pathwaysAngiotensin-converting enzyme inhibitorAcute myocardial infarctionCare of patientsLongitudinal cohort studyProcess of careFirst dayQuality of careCross-sectional analysisReperfusion therapyCohort studyPrincipal diagnosisConnecticut hospitalsPatientsEnzyme inhibitorsYale University SchoolStayClinical Scholars Program
1993
Cost-effectiveness of a smoking cessation program after myocardial infarction
Krumholz H, Cohen B, Tsevat J, Pasternak R, Weinstein M. Cost-effectiveness of a smoking cessation program after myocardial infarction. Journal Of The American College Of Cardiology 1993, 22: 1697-1702. PMID: 8227841, DOI: 10.1016/0735-1097(93)90598-u.Peer-Reviewed Original ResearchConceptsSmoking cessation programAcute myocardial infarctionNurse-managed smoking cessation programCessation programsMyocardial infarctionYears of lifeBeta-adrenergic antagonist therapyLife expectancyOne-way sensitivity analysesTwo-way sensitivity analysesCost-effective interventionHealth care resourcesAntagonist therapySmoking ratesInfarctionCare resourcesSmokersInterventionProgram costsYearsExpectancyTherapyLife